CA2177146A1 - Heterocyclic benzenesulfonylimine derivatives as inhibitors of il-1 action - Google Patents

Heterocyclic benzenesulfonylimine derivatives as inhibitors of il-1 action

Info

Publication number
CA2177146A1
CA2177146A1 CA2177146A CA2177146A CA2177146A1 CA 2177146 A1 CA2177146 A1 CA 2177146A1 CA 2177146 A CA2177146 A CA 2177146A CA 2177146 A CA2177146 A CA 2177146A CA 2177146 A1 CA2177146 A1 CA 2177146A1
Authority
CA
Canada
Prior art keywords
inhibitors
action
heterocyclic
derivatives
benzenesulfonylimine derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2177146A
Other languages
French (fr)
Other versions
CA2177146C (en
Inventor
George Ku
Boyd L. Harrison
David M. Stemerick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2177146A1 publication Critical patent/CA2177146A1/en
Application granted granted Critical
Publication of CA2177146C publication Critical patent/CA2177146C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/68—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with nitrogen atoms directly attached in position 4

Abstract

The present invention relates to heterocyclic benzenesulfonylimine derivatives and their use inhibitors of Interleukin-1(IL-1) action.
Such inhibitors are useful in the treatment of various disease states as disclosed herein including rheumatoid arthritis, multiple sclerosis.
diabetes mellitus, atherosclerosis, septic shock and pulmonary fibrosis.
CA002177146A 1993-11-29 1994-11-03 Heterocyclic benzenesulfonylimine derivatives as inhibitors of il-1 action Expired - Fee Related CA2177146C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15866193A 1993-11-29 1993-11-29
US08/158,661 1993-11-29
PCT/US1994/012575 WO1995014670A1 (en) 1993-11-29 1994-11-03 Heterocyclic benzenesulfonylimine derivatives as inhibitors of il-1 action

Publications (2)

Publication Number Publication Date
CA2177146A1 true CA2177146A1 (en) 1995-06-01
CA2177146C CA2177146C (en) 1999-07-06

Family

ID=22569128

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002177146A Expired - Fee Related CA2177146C (en) 1993-11-29 1994-11-03 Heterocyclic benzenesulfonylimine derivatives as inhibitors of il-1 action

Country Status (20)

Country Link
US (1) US5668143A (en)
EP (1) EP0731792B1 (en)
JP (1) JP3612073B2 (en)
KR (1) KR100351884B1 (en)
CN (1) CN1045596C (en)
AT (1) ATE176225T1 (en)
AU (1) AU682736B2 (en)
CA (1) CA2177146C (en)
DE (1) DE69416324T2 (en)
DK (1) DK0731792T3 (en)
ES (1) ES2129794T3 (en)
FI (1) FI113368B (en)
GR (1) GR3029485T3 (en)
HU (1) HU222819B1 (en)
IL (1) IL111774A (en)
NO (1) NO306158B1 (en)
NZ (1) NZ276570A (en)
TW (1) TW281671B (en)
WO (1) WO1995014670A1 (en)
ZA (1) ZA949301B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09506345A (en) * 1993-11-29 1997-06-24 メレルファーマスーティカルズ インコーポレイテッド Novel benzenesulfonylimine derivatives as inhibitors of IL-1 action
US6562629B1 (en) 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
CA2451699A1 (en) * 2001-06-26 2003-01-09 Beth Israel Deaconess Medical Center Compositions and methods for inhibiting platelet activation and thrombosis
KR100687522B1 (en) * 2005-05-28 2007-02-27 한국화학연구원 Therapeutic agent for antiinflammatory disease induced by pge2 activity containing 2,2-dimethyl-3-ester-4-alkoxy-6-alkyl amino benzopyrane derivatives as an effective ingredient
US9322160B2 (en) 2011-10-28 2016-04-26 Alfred Iseli Method and device for manufacturing ultralight cardboard structures having substantial mechanical stability

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3742951A (en) * 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US3996934A (en) * 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US3921636A (en) * 1973-01-15 1975-11-25 Alza Corp Novel drug delivery device
US4031894A (en) * 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
GB8719102D0 (en) * 1987-08-12 1987-09-16 Merck Sharp & Dohme Therapeutic agents
JP3465794B2 (en) * 1991-02-27 2003-11-10 メレルファーマスーティカルズ インコーポレイテッド NMDA antagonist
JPH05331169A (en) * 1992-05-26 1993-12-14 Sumitomo Pharmaceut Co Ltd Benzonaphthaylidine derivative

Also Published As

Publication number Publication date
EP0731792A1 (en) 1996-09-18
GR3029485T3 (en) 1999-05-28
FI113368B (en) 2004-04-15
AU682736B2 (en) 1997-10-16
CN1045596C (en) 1999-10-13
NO306158B1 (en) 1999-09-27
AU1086895A (en) 1995-06-13
DE69416324T2 (en) 1999-06-10
ATE176225T1 (en) 1999-02-15
ES2129794T3 (en) 1999-06-16
JPH09506344A (en) 1997-06-24
TW281671B (en) 1996-07-21
NZ276570A (en) 2001-02-23
EP0731792B1 (en) 1999-01-27
US5668143A (en) 1997-09-16
NO962156D0 (en) 1996-05-28
CN1136312A (en) 1996-11-20
IL111774A (en) 1999-11-30
FI962236A0 (en) 1996-05-28
HU9601434D0 (en) 1996-07-29
ZA949301B (en) 1995-08-07
IL111774A0 (en) 1995-01-24
DK0731792T3 (en) 1999-09-13
WO1995014670A1 (en) 1995-06-01
JP3612073B2 (en) 2005-01-19
HU222819B1 (en) 2003-11-28
HUT76272A (en) 1997-07-28
KR100351884B1 (en) 2002-12-31
CA2177146C (en) 1999-07-06
NO962156L (en) 1996-05-28
FI962236A (en) 1996-05-28
DE69416324D1 (en) 1999-03-11

Similar Documents

Publication Publication Date Title
CA2010636A1 (en) Substituted pyrroles
CA2270964A1 (en) Benzonaphthyridines as bronchial therapeutics
AU1108395A (en) Heterocyclic biphenylylamides useful as 5ht1d antagonists
CA2175458A1 (en) Novel Benzenesulfonylimine Derivatives as Inhibitors of IL-1 Action
CA2177146A1 (en) Heterocyclic benzenesulfonylimine derivatives as inhibitors of il-1 action
AU5395194A (en) Process for the manufacture of 1,1,1,2-tetrafluoro-2- chloroethane and of pentafluoroethane
AU6246394A (en) Use of heparin to inhibit interleukin-8
AU3240293A (en) 3-hydryl-F-oxetane and 3,3-dihydryl-F-oxetane compounds useful as refrigerants or solvents
KR950003268U (en) 3, 4 axis structure of horizontal articulated robot
RU93004798A (en) NEW AZETIDINE DERIVATIVES
Dozeman The Life of Moses: The Yahwist as Historian in Exodus-Numbers
Wang Nonlinear response of an articulated offshore tower
FR2708691B1 (en) Shock absorption structure.
AU7384494A (en) Quantification of active plasminogen-activator-inhibitor-type-1
ITPA930016A0 (en) ADAPTIVE ACTIVE SUSPENSION.
ITPA930018V0 (en) ADAPTIVE ACTIVE SUSPENSIONS
BR7301398U (en) Double action matchstick
TH18277EX (en) Cart
CA2177955A1 (en) Use of dimeticone for treating constipation
CA2195663A1 (en) Dihydrobenzofuranes

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20131105

MKLA Lapsed

Effective date: 20131105